Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 1/20 | 0.54 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.54 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.54 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6541474 | 0.89 | POLB (0.50) | MTNR1BMTNR1AKMT2A | |
| SCHEMBL6677132 | 0.83 | HTT (0.42) | NAMPT | |
| SCHEMBL5073633 | 0.83 | MTNR1A (0.71) | MTNR1BMTNR1AKMT2AMEN1 | |
| SCHEMBL6680430 | 0.82 | ALK (0.47) | KMT2ANAMPT | |
| SCHEMBL6679300 | 0.81 | NLRP3 (0.42) | — | |
| SCHEMBL5072982 | 0.80 | POLB (0.58) | MTNR1BMTNR1A | |
| SCHEMBL6803966 | 0.80 | RAB9A (0.44) | MTNR1BMTNR1AKMT2AMEN1 | |
| SCHEMBL6806399 | 0.80 | CA2 (0.43) | MTNR1BMTNR1AKMT2AMEN1 | |
| SCHEMBL6677462 | 0.80 | MTNR1A (0.51) | MTNR1BMTNR1AKMT2AMEN1 | |
| SCHEMBL6540502 | 0.80 | ABCC9 (0.54) | ABCC9ABCC8KCNJ11KCNJ8KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106653-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| WO-2004045610-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106653-A1 | Aminoalcohol derivatives | FANCD2, FANCI, HRH2 | ABCC9 1596/4885ABCC8 997/4885KCNJ11 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.